API Data Insights

In Focus

View All

The 21% Correction: Why Public Markets Are No Longer Buying Biotech Platforms Without Clinical Anchors

The biotech markets of early 2026 have become a theater of the extreme, where the ethereal promises of silicon-based discovery…

admin March 4, 2026March 4, 2026

Market Watch

Stop Searching, Start Connecting: Your Global API & FDF Hub

admin February 20, 2026February 20, 2026

Market Watch Signals

Checkbook Darwinism: Why Merck and Roche Are Paying ‘Panic Premiums’ to Avert Extinction

admin December 11, 2025December 11, 2025

Market Watch Signals

Regulatory Shock Trades: How FDA Letters Move Billions Before Lunch

admin October 14, 2025October 15, 2025

Case Files Signals

Data Integrity’s New Price Tag: How Compliance Failures Now Move Stock Prices in Hours

admin October 10, 2025October 10, 2025

Newswire

Novo Nordisk Introduces Subscription Model for Wegovy Weight Loss Treatments

On Tuesday, Novo Nordisk announced its innovative approach to selling Wegovy, its weight loss drug, by introducing a subscription model for its shots and pills. This move marks a significant shift in the pharmaceutical industry, where subscription services have been largely limited to consumer goods and digital platforms. This model could potentially reshape the landscape […]

April 3, 2026

Newswire

HHS Reverts Health IT Office Name and Focus to ONC

The U.S. Department of Health and Human Services (HHS) has officially reverted the name of its health IT office to the Office of the National Coordinator for Health Information Technology (ONC), a move announced earlier this week. This change also shifts the office’s focus back to external IT coordination, removing oversight of HHS’s internal technology […]

April 3, 2026

Newswire

Astellas Does Not Exercise Option on AviadoBio’s Gene Therapy, Nonprofit Funding to Propel Development

Astellas has opted not to exercise its option on AviadoBio’s gene therapy aimed at treating frontotemporal dementia, as disclosed by the UK biotech company on Tuesday. This decision highlights the growing challenges and complexities faced by pharmaceutical companies in the gene therapy landscape, particularly in the context of emerging data and market dynamics. The implications […]

April 3, 2026

Newswire

Celiac Disease Study Reveals Fiber Benefits Depend on Gut Microbiome

The recent study published in Nature Communications highlights a critical finding regarding celiac disease: the benefits of dietary fiber are significantly influenced by the gut microbiome. Celiac disease, an autoimmune disorder triggered by gluten, leads to mucosal damage in the small intestine and often results in nutrient deficiencies, including fiber. While patients are typically advised […]

April 2, 2026

Newswire

FDA flags serious liver injury cases, 8 deaths with ‘reasonable’ link to Amgen’s Tavneos

The U.S. Food and Drug Administration (FDA) has identified 76 cases of drug-induced liver injury associated with Amgen’s Tavneos, a treatment primarily indicated for the management of certain autoimmune conditions. Among these cases, eight fatalities were reported, raising significant concerns regarding the safety profile of the drug. This alarming data comes as the FDA continues […]

April 2, 2026

Recently Featured

Drugmakers Delay European Launches Amid U.S. Pricing Pressure; Eli Lilly Acquires Centessa Pharmaceuticals

April 1, 2026

Drugmakers are delaying launches of some new medicines in Europe as the industry grapples with U.S. pressure and pricing policy shifts from President Trump, according to Reuters. The White House has been pushing to lower the cost of prescription drugs in the U.S., which has traditionally paid significantly more than other wealthy countries. Trump asserts…

Avo Secures $10 Million to Enhance Physician Workflow Efficiency

April 1, 2026

Avo, a startup leveraging patient health records to streamline administrative tasks for physicians, has successfully raised $10 million in funding, as reported exclusively by Endpoints News. This financial boost is aimed at enhancing Avo’s innovative platform, which assists doctors in managing paperwork and making informed decisions during patient visits. The significance of this funding lies…

PRISM ALS: New Stem Cell Models Could Transform Research Into Treatments for MND/ALS

April 1, 2026

A new global initiative launched today aims to close a critical gap in ALS/MND drug discovery – current cell models used for testing treatments do not currently reflect the diverse nature of the disease – that affects both researchers developing therapies and the people urgently waiting for them. The ALS Therapy Development Institute (ALS TDI),…

Symeres & Ambagon Therapeutics Collaborate on Molecular Glue Research in Colorectal Cancer

April 1, 2026

Symeres has recently partnered with Ambagon Therapeutics, a pre-clinical biotechnology company, to explore a new class of small molecules, known as molecular glues, for potential use in colorectal cancer and other hard-to-target diseases. Molecular glues represent an emerging therapeutic modality that enables or stabilizes interactions between proteins, offering an alternative to conventional inhibitors or activators.…

Ongoing Cases

Market Watch Signals

The 21% Correction: Why Public Markets Are No Longer Buying Biotech Platforms Without Clinical Anchors

March 4, 2026March 4, 2026

The biotech markets of early 2026 have become a theater of the extreme, where the…

Market Watch

Stop Searching, Start Connecting: Your Global API & FDF Hub

February 20, 2026February 20, 2026

If you’ve been in the pharma business for a while, you know that finding a…

Market Watch Signals

Checkbook Darwinism: Why Merck and Roche Are Paying ‘Panic Premiums’ to Avert Extinction

December 11, 2025December 11, 2025

The pharmaceutical sector has officially transitioned from cautious capital preservation to a state of aggressive,…

Market Watch Signals

Regulatory Shock Trades: How FDA Letters Move Billions Before Lunch

October 14, 2025October 15, 2025

CRL Regulatory Shock Trades: How FDA Letters Move Billions Before Lunch No fireworks. A 7:12…

Case Files Signals

Data Integrity’s New Price Tag: How Compliance Failures Now Move Stock Prices in Hours

October 10, 2025October 10, 2025

At 9:15 a.m. Mumbai time, Nov. 6, 2015, a single document changed billions in market…

Deep Dives Regulatory

Regulatory Pressure & Supply Shock: Why Europe’s Drug Shortages Became Chronic – and What Everyone’s Missing

September 20, 2025September 20, 2025

“Shortages aren’t accidents; they’re features of how the market is built.” Outside declared emergencies EMA…

Signals

Nitrosamines 2.0: new AI thresholds, new “casualties,” and finally predictable rules

September 10, 2025September 10, 2025

The story really does begin in a hot stretch of 2025, when three regulators –…

Opinion Deep Dives

Cracking Down on Orphan Drug Abuse: The ORPHAN Cures Act and Its Impact

August 23, 2025August 23, 2025

Orphan Drug Profits vs. Patients: The Orphan Drug Act of 1983 was meant to encourage…

Market Watch Opinion

Britain’s Big Pharma Showdown: NHS Drug Levy Sparks £11 Billion R&D Exodus Threat

August 23, 2025August 23, 2025

LONDON, June 4, 2025 – A storm is brewing between the UK’s National Health Service…

Supply Chain Market Watch

Dirty Pills and Empty Shelves: How Outsourcing Broke America’s Drug Supply

August 23, 2025August 23, 2025

Imagine being told your chemotherapy is postponed because the only factory making the drug was…

In Focus

The 21% Correction: Why Public Markets Are No Longer Buying Biotech Platforms Without Clinical Anchors

Stop Searching, Start Connecting: Your Global API & FDF Hub

Checkbook Darwinism: Why Merck and Roche Are Paying ‘Panic Premiums’ to Avert Extinction

Regulatory Shock Trades: How FDA Letters Move Billions Before Lunch

Data Integrity’s New Price Tag: How Compliance Failures Now Move Stock Prices in Hours

Novo Nordisk Introduces Subscription Model for Wegovy Weight Loss Treatments

HHS Reverts Health IT Office Name and Focus to ONC

Astellas Does Not Exercise Option on AviadoBio’s Gene Therapy, Nonprofit Funding to Propel Development

Celiac Disease Study Reveals Fiber Benefits Depend on Gut Microbiome

FDA flags serious liver injury cases, 8 deaths with ‘reasonable’ link to Amgen’s Tavneos

Drugmakers Delay European Launches Amid U.S. Pricing Pressure; Eli Lilly Acquires Centessa Pharmaceuticals

Avo Secures $10 Million to Enhance Physician Workflow Efficiency

PRISM ALS: New Stem Cell Models Could Transform Research Into Treatments for MND/ALS

Symeres & Ambagon Therapeutics Collaborate on Molecular Glue Research in Colorectal Cancer

Ongoing Cases

The 21% Correction: Why Public Markets Are No Longer Buying Biotech Platforms Without Clinical Anchors

Stop Searching, Start Connecting: Your Global API & FDF Hub

Checkbook Darwinism: Why Merck and Roche Are Paying ‘Panic Premiums’ to Avert Extinction

Regulatory Shock Trades: How FDA Letters Move Billions Before Lunch

Data Integrity’s New Price Tag: How Compliance Failures Now Move Stock Prices in Hours

Regulatory Pressure & Supply Shock: Why Europe’s Drug Shortages Became Chronic – and What Everyone’s Missing

Nitrosamines 2.0: new AI thresholds, new “casualties,” and finally predictable rules

Cracking Down on Orphan Drug Abuse: The ORPHAN Cures Act and Its Impact

Britain’s Big Pharma Showdown: NHS Drug Levy Sparks £11 Billion R&D Exodus Threat

Dirty Pills and Empty Shelves: How Outsourcing Broke America’s Drug Supply

About Us

Contact & Support

Connect